Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure.
|
31512149 |
2020 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Search inclusion criteria included studies describing either the incidence of HK events and any associated risk factors, or associations between HK or serum potassium concentration and adverse clinical outcomes including mortality, hospitalisation, major adverse cardiac events (MACE) and renin-angiotensin-aldosterone system inhibitors (RAASi) discontinuation in adult patients with chronic kidney disease (CKD), heart failure (HF), type 2 diabetes (T2DM) or hypertension.
|
31532067 |
2020 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of dual renin-angiotensin system (RAS) inhibition in heart failure (HF) is still controversial.
|
31814505 |
2020 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Current cardiovascular pharmacotherapy targets maladaptive overactivation of the renin-angiotensin-aldosterone system (RAAS), which occurs throughout the continuum of cardiovascular disease spanning from hypertension to heart failure with reduced ejection fraction.
|
31786973 |
2020 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In addition, the efficacy of medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers has not been defined in TRC.
|
30859381 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
This has been heralded as a step toward filling a crucial gap in HF management by providing strong evidence that combined inhibition of the angiotensin receptor and neprilysin is superior to inhibition of the renin-angiotensin system alone in stable patients with chronic HF as it negates the deleterious effects of angiotensin while concomitantly augmenting the beneficial effects of the endogenous natriuretic peptide system.
|
29926350 |
2019 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Elderly heart failure with reduced ejection fraction patients (≥75 years) received significantly fewer beta-blockers (77.8% vs. 84.2%), renin-angiotensin system inhibitors (75.2% vs. 89.7%), mineralocorticoid receptor antagonists (50.6% vs. 59.6%) and ivabradine (2.9% vs. 9.3%), but significantly more diuretics (88.1% vs. 72.6%) compared to patients aged less than 60 years (<i>P</i><sub>for all trends</sub> < 0.01).
|
30866680 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Although renin-angiotensin aldosterone system (RAAS) inhibitors have become the mainstay treatment for patients with chronic diseases, hyperkalemia is a major contributory deterrent to their use in patients with chronic kidney disease (CKD) and heart failure.
|
30865167 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments.
|
30836981 |
2019 |
Congestive heart failure
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Modulation of renin activity in experimental HF significantly reduces edema formation and the progression of systolic dysfunction and improves survival.
|
31261774 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Excessive activation of the renin-angiotensin system (RAS) in diabetic cardiomyopathy (DCM) provokes a series of structural and functional abnormalities, and causes ventricular remodeling and heart failure in diabetes.
|
30952701 |
2019 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
However, this has not been confirmed and standard medical treatment for heart failure (HF) including renin-angiotensin inhibitors and β-blockers may lead to its recovery.
|
30367208 |
2019 |
Congestive heart failure
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Hyperkalemia (HK) is the most common electrolyte disturbance observed in patients with kidney disease, particularly in those in whom diabetes and heart failure are present or are on treatment with renin-angiotensin-aldosterone system inhibitors (RAASIs).
|
31119681 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The pharmacological inhibition of the renin-angiotensin-aldosterone system as a therapeutic strategy is one of the most significant advances in the treatment and prevention of cardiovascular disease in heart failure with reduced ejection fraction and in coronary artery disease.
|
31370961 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, while renin-angiotensin-aldosterone system inhibitors (RAASIs) represent the most cardio-nephro-protective drugs used in clinical practice, the treatment with these drugs per se increases serum potassium (sK) values, particularly when heart failure and diabetes mellitus coexist.
|
31800075 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We conclude that Angs of the alternative renin-angiotensin system seem to play a role in HF with preserved ejection fraction and are linked to outcome in patients with HF and preserved ejection fraction.
|
31230551 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Sympathetic and renin-angiotensin-aldosterone system activation in heart failure with preserved, mid-range and reduced ejection fraction.
|
31443984 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We examined predictors for repeated hyperkalemia among patients after first-time renin angiotensin system inhibitor (RASi) prescription, chronic kidney disease (CKD), or chronic heart failure (CHF); and we also examined potassium trajectories in these patients after their first hyperkalemia event.
|
31226134 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibitors of the renin-angiotensin-aldosterone (RAAS) system are cornerstones of the management of patients with heart failure with reduced left ventricular ejection fraction (HFrEF).
|
31118203 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
We discuss the complex interplay of kidney function and heart failure in the presence of renin-angiotensin-aldosterone system agents and suggest a clinical algorithm for management of acute decline in kidney function.
|
31648696 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The Prospective comparison of Angiotensin Receptor-neprilysin inhibitor (ARNI) with Angiotensin converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (HF) trial (PARADIGM-HF) showed that adding a neprilysin inhibitor (sacubitril) to a renin-angiotensin system blocker (and other standard therapy) reduced morbidity and mortality in ambulatory patients with chronic HF with reduced ejection fraction (HFrEF).
|
31172710 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
The new pharmacological class of angiotensin (Ang) receptor-neprilysin inhibitors (ARNI) prompted a real conceptual change in the treatment of HF moving from only the inhibition of the renin-Ang-aldosterone system and sympathetic nervous system to a strategy based on the concomitant pharmacological enhancement of endogenous natriuretic peptides.
|
31432436 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Elderly, patients with chronic kidney disease (CKD) and patients with heart failure who continue using renin-angiotensin-aldosterone-system (RAAS) inhibitors, diuretics, or non-steroidal-anti-inflammatory drugs (NSAIDs) during times of fluid loss have a high risk of developing complications like acute kidney injury (AKI).
|
31801476 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
Medical therapy of heart failure including renin-angiotensin-aldosterone system inhibition and β-adrenergic blockade can blunt these deleterious processes.
|
31300181 |
2019 |
Congestive heart failure
|
0.400 |
Biomarker
|
disease |
BEFREE |
A significant subset of patients with heart failure (HF) experience small to moderate rise in serum creatinine (RSC) in the setting of otherwise beneficial therapies such as aggressive diuresis or renin-angiotensin-aldosterone system (RAAS) inhibition.
|
31216531 |
2019 |